Skip to main content

Hidradenitis Suppurativa News

Findings from a recent study showed patients with hidradenitis suppurativa may have an increased risk of developing cancer, including Hodgkin lymphoma and nonmelanoma skin cancer.
Findings from a recent study indicated that several comorbidities precede a diagnosis of hidradenitis suppurativa, and that several develop afterwards.
Findings from an open label cohort study showed treatment of moderate to severe hidradenitis suppurativa with an IL-17 inhibitor was associated clinical response and had a favorable safety profile.
Findings from a recent study showed a potential association between birth weight and childhood weight and the risk of developing hidradenitis suppurativa in adulthood.
In a recent study, researchers assessed the prevalence of inflammatory eye disease and treatment outcomes among patients with hidradenitis suppurativa.
A recent systemic review showed patients with hidradenitis suppurativa who underwent partial excision had higher recurrence rates compared with wide excision.
A recent study showed only 32% of patients with hidradenitis suppurativa who are overweight or obese receive weight counseling, which suggests more awareness and education about weight management and nutrition among this patient population.
A recent study identified a possible ‘window of opportunity’ for initiating adalimumab that could predict treatment response among patients with hidradenitis suppurativa.
Hidradenitis suppurativa (HS) is associated with lower quality of life. Findings from a recent study showed arthralgia can exacerbate this burden in patients.
The use of complementary and alternative medicine among patients with HS is very common, according to the findings of a recent survey, which also showed nearly 50% of patients did not find conventional therapy very successful for treating their skin disease.
Back to Top